TY - JOUR AU - Holmøy, Trygve AU - Fevang, Børre AU - Olsen, David Benee AU - Spigset, Olav AU - Bø, Lars PY - 2019 DA - 2019/08/12 TI - Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis JO - BMC Research Notes SP - 497 VL - 12 IS - 1 AB - Sporadic fatal adverse events have been reported during treatment of multiple sclerosis with alemtuzumab. To provide a systematic overview, we searched the centralized European Medicines Agency database of suspected adverse reactions related to medicinal products (EudraVigilance) for fatal adverse events associated with treatment with alemtuzumab (Lemtrada®) for multiple sclerosis. Four independent reviewers with expertise on MS, clinical immunology, infectious diseases and clinical pharmacology reviewed the reports, and scored the likelihood for causality. SN - 1756-0500 UR - https://doi.org/10.1186/s13104-019-4507-6 DO - 10.1186/s13104-019-4507-6 ID - Holmøy2019 ER -